NCT00289133

Brief Summary

The purpose of this study is to evaluate long-term clinical and radiographic data between geometrically identical GVF and cross-linked polyethylene-bearing inserts in total knee arthroplasty.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
938

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Feb 2005

Longer than P75 for not_applicable

Geographic Reach
1 country

9 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2005

Completed
1 year until next milestone

First Submitted

Initial submission to the registry

February 7, 2006

Completed
2 days until next milestone

First Posted

Study publicly available on registry

February 9, 2006

Completed
7.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2013

Completed
3.2 years until next milestone

Results Posted

Study results publicly available

July 15, 2016

Completed
Last Updated

April 24, 2017

Status Verified

March 1, 2017

Enrollment Period

8.2 years

First QC Date

February 7, 2006

Results QC Date

May 30, 2014

Last Update Submit

March 23, 2017

Conditions

Keywords

Arthroplasty, Replacement, Knee

Outcome Measures

Primary Outcomes (1)

  • Survivorship (Revision of Any Component for Any Reason)

    Survival was estimated by Kaplan-Meier method. Kaplan Meier survivorship analysis estimates the proportion of a population that will survive past a certain time avoiding a certain event. In this study, the event is removal of any component for any reason, also known as revision for any reason. Survival estimates are provided when 40 devices are left still being followed.

    5 years

Secondary Outcomes (8)

  • American Knee Society Evaluation - Total Score

    2 year

  • American Knee Society Evaluation - Total Score

    Minimum 5 years, up to 7.6 years

  • Western Ontario and McMaster Universities Arthritis Index (WOMAC) Osteoarthritis Total Score

    2 year

  • Western Ontario and McMaster Universities Arthritis Index (WOMAC) Osteoarthritis Total Score

    Minimum 5 years, up to 7.6 years

  • Radiographic Outcomes - Percentage of Knees With Femoral Radiolucencies (>2mm)

    Minimum 5 years, up to 7.6 years

  • +3 more secondary outcomes

Study Arms (2)

GVF

ACTIVE COMPARATOR

Gamma Vacuum Foil polyethylene tibial insert

Device: total knee arthroplasty

P.F.C.

ACTIVE COMPARATOR

Cross-linked polyethylene tibial insert

Device: total knee arthroplasty

Interventions

Gamma Vacuum Foil polyethylene tibial insert

GVF

Eligibility Criteria

AgeUp to 80 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Osteoarthritis of the affected joint appropriate for Total Knee Arthroplasty.
  • Diagnosis of any of the following: rheumatoid or other inflammatory arthritis, post-traumatic arthritis, juvenile rheumatoid arthritis.
  • Radiographic evidence of sufficient sound bone stock to seat and support the prosthesis.
  • Subject requires a primary total knee replacement and is considered to be suitable for the specific knee prosthesis identified in protocol.
  • Subject has given consent to the transfer of his/her information to sponsor.
  • Subject will be compliant with requirements of protocol by returning for follow-up visits.

You may not qualify if:

  • History of recent/active joint sepsis.
  • Charcot neuropathy.
  • Psycho-social disorders that would limit rehabilitation.
  • Women who are pregnant or planning on being pregnant.
  • Greater than 80 years of age at the time of surgery.
  • Prior ipsilateral knee arthroplasty.
  • Metabolic disorders of calcified tissues, such as Paget's disease.
  • Severe diabetes mellitus that is not controlled by diet or oral agents.
  • Require joint replacement due to immunodeficiency syndromes.
  • Skeletal immaturity.
  • Avascular necrosis of the affected knee.
  • Chronic renal disease.
  • Subjects involved in medical-legal or worker's compensation claims.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (9)

Alabama Orthopaedic Clinic

Mobile, Alabama, 36608, United States

Location

Pacific Bone and Joint Clinic

Berkley, California, 94705, United States

Location

Orthopedic Center of the Rockies

Fort Collins, Colorado, 80525, United States

Location

Holy Cross Hospital

Fort Lauderdale, Florida, 33308, United States

Location

Jewett Orthopaedic Clinic

Orlando, Florida, 32817, United States

Location

Jewett Orthopaedic Clinic

Winter Park, Florida, 32792, United States

Location

Loyola University

Chicago, Illinois, 60153, United States

Location

Rockford Orthopedic Associates

Rockford, Illinois, 61107, United States

Location

Orthopaedic & Spine Specialists

York, Pennsylvania, 17402, United States

Location

MeSH Terms

Conditions

Osteoarthritis, KneeArthritis, Rheumatoid

Interventions

Arthroplasty, Replacement, Knee

Condition Hierarchy (Ancestors)

OsteoarthritisArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System Diseases

Intervention Hierarchy (Ancestors)

Arthroplasty, ReplacementArthroplastyOrthopedic ProceduresSurgical Procedures, OperativePlastic Surgery ProceduresProsthesis Implantation

Limitations and Caveats

Serious adverse events were not collected in this study per the modern definition. All adverse events collected for this study will be reported in the 'Other Adverse Events' table. MedDRA was used to classify each AE into SOC, but not Preferred Term.

Results Point of Contact

Title
Clinical Portfolio Leader
Organization
DePuy Orthopaedics, Inc.

Study Officials

  • Gracia Etienne, MD

    Orthopaedic & Spine Specialists

    PRINCIPAL INVESTIGATOR
  • Michael L. Granberry, MD

    Alabama Orthopaedic Clinic

    PRINCIPAL INVESTIGATOR
  • Richard M. Konsens, MD

    Jewett Orthopaedic Clinic

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 7, 2006

First Posted

February 9, 2006

Study Start

February 1, 2005

Primary Completion

May 1, 2013

Study Completion

May 1, 2013

Last Updated

April 24, 2017

Results First Posted

July 15, 2016

Record last verified: 2017-03

Locations